Nektar Therapeutics (NKTR) Set to Announce Earnings on Thursday

Nektar Therapeutics (NASDAQ:NKTR) is set to post its quarterly earnings results after the market closes on Thursday, November 7th. Analysts expect Nektar Therapeutics to post earnings of ($0.23) per share for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.04). The business had revenue of $23.49 million for the quarter, compared to analyst estimates of $17.24 million. Nektar Therapeutics had a negative return on equity of 133.64% and a negative net margin of 190.09%. During the same period in the previous year, the business posted ($0.27) EPS. On average, analysts expect Nektar Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Nektar Therapeutics Stock Performance

NASDAQ:NKTR traded up $0.06 on Tuesday, reaching $1.39. The company’s stock had a trading volume of 1,686,754 shares, compared to its average volume of 1,749,704. Nektar Therapeutics has a 1-year low of $0.41 and a 1-year high of $1.93. The business’s 50-day moving average price is $1.28 and its two-hundred day moving average price is $1.34. The firm has a market cap of $254.95 million, a PE ratio of -1.56 and a beta of 0.61.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. BTIG Research reiterated a “buy” rating and issued a $4.00 price objective on shares of Nektar Therapeutics in a research report on Monday, September 30th. Piper Sandler assumed coverage on shares of Nektar Therapeutics in a report on Monday. They issued an “overweight” rating and a $7.00 price target for the company. One research analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company. According to MarketBeat.com, Nektar Therapeutics has an average rating of “Hold” and an average price target of $3.50.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.